Your browser is no longer supported. Please, upgrade your browser.
Settings
OPHT Ophthotech Corporation daily Stock Chart
OPHT [NASD]
Ophthotech Corporation
Index- P/E0.54 EPS (ttm)4.25 Insider Own0.41% Shs Outstand36.21M Perf Week-0.43%
Market Cap83.65M Forward P/E- EPS next Y-1.18 Insider Trans-1.81% Shs Float35.96M Perf Month-1.70%
Income153.20M PEG- EPS next Q-0.43 Inst Own62.20% Short Float1.20% Perf Quarter-12.50%
Sales206.70M P/S0.40 EPS this Y158.20% Inst Trans8.53% Short Ratio3.54 Perf Half Y-12.83%
Book/sh0.48 P/B4.81 EPS next Y24.40% ROA91.30% Target Price3.25 Perf Year-7.97%
Cash/sh- P/C- EPS next 5Y- ROE480.70% 52W Range2.25 - 4.50 Perf YTD-25.96%
Dividend- P/FCF- EPS past 5Y17.20% ROI296.60% 52W High-48.67% Beta1.17
Dividend %- Quick Ratio16.20 Sales past 5Y- Gross Margin- 52W Low2.67% ATR0.08
Employees38 Current Ratio16.20 Sales Q/Q- Oper. Margin- RSI (14)44.13 Volatility2.90% 3.50%
OptionableYes Debt/Eq0.00 EPS Q/Q41.10% Profit Margin74.20% Rel Volume0.31 Prev Close2.28
ShortableYes LT Debt/Eq0.00 EarningsNov 07 BMO Payout0.00% Avg Volume121.53K Price2.31
Recom3.30 SMA20-2.96% SMA50-4.14% SMA200-14.39% Volume38,219 Change1.32%
Mar-19-18Downgrade JP Morgan Neutral → Underweight
Feb-28-18Reiterated Chardan Capital Markets Neutral $3 → $4
Dec-13-16Upgrade Goldman Sell → Neutral
Dec-13-16Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-13-16Downgrade Gabelli & Co Buy → Hold
Dec-12-16Downgrade Leerink Partners Outperform → Mkt Perform
Dec-12-16Downgrade JP Morgan Overweight → Neutral
Dec-12-16Downgrade Citigroup Buy → Neutral
Dec-12-16Downgrade Chardan Capital Markets Buy → Neutral $200 → $15
Jun-02-16Upgrade JP Morgan Neutral → Overweight
Apr-27-16Initiated Barclays Overweight $85
Jan-08-16Initiated Sun Trust Rbsn Humphrey Buy $100
Jan-07-16Initiated Sun Trust Rbsn Humphrey Buy
Dec-14-15Reiterated Chardan Capital Markets Buy $125 → $200
Sep-08-15Reiterated Chardan Capital Markets Buy $105 → $125
Sep-03-15Initiated Citigroup Buy
Aug-14-15Resumed Oppenheimer Outperform $95
Aug-07-15Downgrade Goldman Neutral → Sell
Aug-06-15Reiterated Stifel Buy $74 → $83
Aug-03-15Reiterated Leerink Partners Outperform $69 → $92
Oct-15-18 07:50AM  Investor Expectations to Drive Momentum within Echo Global Logistics, Sanderson Farms, Ophthotech, CarGurus, Avon Products, and Kemet Discovering Underlying Factors of Influence GlobeNewswire
Oct-04-18 07:30AM  Ophthotech Completes Patient Recruitment As Planned for its Phase 2b Clinical Trial of Zimura® Monotherapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Business Wire
Oct-03-18 07:30AM  Ophthotech Corporation to Present at Chardans 2nd Annual Genetic Medicines Conference Business Wire
Sep-12-18 03:11PM  Is Ophthotech Corporation (NASDAQ:OPHT) Attractive At Its Current PE Ratio? Simply Wall St.
Aug-31-18 11:38AM  Why Is Ophthotech (OPHT) Up 5.8% Since Last Earnings Report? Zacks
Aug-22-18 07:30AM  Scientific Data for Novel Adeno-Associated Virus Gene Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa Published in Proceedings of the National Academy of Sciences Business Wire
Aug-17-18 05:40PM  Edited Transcript of OPHT earnings conference call or presentation 1-Aug-18 12:00pm GMT Thomson Reuters StreetEvents
Aug-13-18 07:50AM  Report: Developing Opportunities within Energy Recovery, Lamb Weston, Neurocrine Biosciences, Pioneer Natural Resources, Meritor, and Ophthotech Future Expectations, Projections Moving into 2018 GlobeNewswire
Aug-02-18 10:35AM  Ophthotech (OPHT) Q2 Loss Narrows, Zimura Progress On Track Zacks
Aug-01-18 07:27AM  Ophthotech: 2Q Earnings Snapshot Associated Press
07:15AM  Ophthotech Reports Second Quarter 2018 Financial and Operating Results Business Wire
06:00AM  Ophthotech Corp. to Host Earnings Call ACCESSWIRE
Jul-31-18 07:31PM  Robbins Arroyo LLP: Ophthotech Corporation (OPHT) Misled Shareholders According to a Consolidated Amended Class Action Complaint Business Wire
Jul-25-18 04:05PM  Ophthotech Corporation to Report Second Quarter 2018 Financial Results and Host Conference Call on Wednesday, August 1, 2018 Business Wire
Jul-17-18 07:25AM  Free Technical Research on OPKO Health and Three More Biotech Equities ACCESSWIRE
Jul-10-18 08:00AM  electroCore, Inc. Announces Additions to Board of Directors in Connection with Recently Completed Initial Public Offering GlobeNewswire
Jun-08-18 08:41AM  Ophthotech (OPHT) Soars: Stock Adds 10.4% in Session Zacks
08:00AM  Todays Research Reports on Stocks to Watch: Proteostasis Therapeutics and Ophthotech Corporation ACCESSWIRE
Jun-07-18 07:00AM  Ophthotech Enters into Gene Therapy Agreements with the University of Florida and the University of Pennsylvania Business Wire +10.36%
May-15-18 11:52PM  Edited Transcript of OPHT earnings conference call or presentation 9-May-18 12:00pm GMT Thomson Reuters StreetEvents
May-14-18 07:30AM  Recent Analysis Shows PHH, Stanley Black & Decker, Invacare, Ophthotech, Party City Holdco, and Hyatt Hotels Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
May-10-18 10:41AM  Ophthotech's (OPHT) Q1 Loss Narrows Y/Y, Zimura in Focus Zacks
May-09-18 07:39AM  Ophthotech: 1Q Earnings Snapshot Associated Press
07:00AM  Ophthotech Reports First Quarter 2018 Financial and Operating Results Business Wire
May-03-18 07:10AM  Wired News Ophthotech Announced Completion of Patient Enrollment in Phase-2a Clinical Trial of Zimura(R) in Wet Age-Related Macular Degeneration ACCESSWIRE
May-01-18 07:35AM  Ophthotech Completes Patient Recruitment in the Phase 2a Clinical Trial of Zimura® in Combination with Anti-VEGF Therapy in Wet Age-Related Macular Degeneration Business Wire
07:30AM  Ophthotech Corporation to Report First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018 Business Wire
Mar-20-18 05:48PM  Regeneron Eylea Hits 24-Week Primary Endpoint in Study Zacks
Mar-19-18 12:45PM  Eeny, Meeny, Miny, Moe: JPMorgan Downgrades 4 Biotechs In Portfolio Rebalancing Benzinga
Mar-06-18 07:30AM  Ophthotech to Present at the Cowen and Company 38th Annual Health Care Conference Business Wire +5.07%
Mar-01-18 07:20AM  Blog Exposure - Ophthotech Initiates Research Collaborations to Discover Treatments for Orphan and Age-Related Retinal Diseases ACCESSWIRE
Feb-28-18 09:04AM  Ophthotech (OPHT) Q4 Earnings Beat, Gene Therapy in Focus Zacks +5.04%
Feb-27-18 08:01PM  Edited Transcript of OPHT earnings conference call or presentation 27-Feb-18 1:00pm GMT Thomson Reuters StreetEvents
06:59AM  Ophthotech reports 4Q loss Associated Press
06:33AM  Ophthotech Reports Fourth Quarter and Full Year 2017 Financial and Operating Results Business Wire
06:30AM  Ophthotech Targets Gene Therapy to Expand its Orphan and Age-Related Retinal Disease Strategy Business Wire
06:00AM  Ophthotech Corp. to Host Earnings Call ACCESSWIRE
Feb-21-18 07:30AM  Ophthotech Corporation to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Tuesday, February 27, 2018 Business Wire
Feb-09-18 08:25AM  Market Trends Toward New Normal in Innospec, Southern Copper, Cornerstone OnDemand, Eagle, Northwest Natural Gas, and Ophthotech Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Jan-24-18 07:33AM  Nektars Deals: Daiichi Sankyo, Ophthotech, Bristol-Myers Squibb Market Realist -5.06%
Jan-17-18 09:56AM  Ophthotech Begins Phase II Zimura Study in Stargardt Disease Zacks
Jan-16-18 07:30AM  Ophthotech Announces First Patient Enrolled in the Phase 2b Clinical Trial of Zimura®, Complement C5 Inhibitor, for the Treatment of Autosomal Recessive Stargardt Disease (STGD1) Business Wire
07:15AM  Ophthotech Announces Election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to Its Board of Directors Business Wire
Jan-02-18 07:30AM  Ophthotech Corporation to Present at the 36th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-13-17 02:12PM  Robbins Arroyo LLP Is Investigating the Officers and Directors of Ophthotech Corporation (OPHT) on Behalf of Shareholders Business Wire
Dec-12-17 05:49PM  Regeneron's sBLA for Eylea Accepted by FDA, Action Date Set Zacks
Dec-11-17 05:02AM  Ophthotech (OPHT) Up 7.1% Since Earnings Report: Can It Continue? Zacks
Nov-21-17 07:50AM  Report: Exploring Fundamental Drivers Behind Carter's, Southern Copper, ViaSat, Bruker, Fred's, and Ophthotech New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-20-17 01:01PM  ETFs with exposure to Ophthotech Corp. : November 20, 2017 Capital Cube
Nov-14-17 08:43AM  Ophthotech (OPHT) Jumps: Stock Rises 11.9% Zacks
Nov-13-17 08:31PM  Edited Transcript of OPHT earnings conference call or presentation 8-Nov-17 1:00pm GMT Thomson Reuters StreetEvents +11.89%
02:20PM  Vertex Gets CHMP Recommendation for Orkambi Label Expansion Zacks
Nov-10-17 12:46PM  ETFs with exposure to Ophthotech Corp. : November 10, 2017 Capital Cube
Nov-09-17 09:48AM  Ophthotech Corp. :OPHT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017 Capital Cube
09:16AM  Ophthotech (OPHT) Q3 Earnings & Sales Beat, Zimura in Focus Zacks
08:10AM  Todays Research Reports on Stocks to Watch: Ophthotech Corporation and HTG Molecular Diagnostics ACCESSWIRE
Nov-08-17 09:30AM  Ophthotech Soars After Third-Quarter Results -- Biotech Movers TheStreet.com +15.88%
07:22AM  Ophthotech posts 3Q profit Associated Press
07:00AM  Ophthotech Reports Third Quarter 2017 Financial and Operating Results Business Wire
06:00AM  Ophthotech Corp. to Host Earnings Call ACCESSWIRE
Oct-30-17 07:30AM  Ophthotech Corporation to Report Third Quarter 2017 Financial Results and Host Conference Call on Wednesday, November 8, 2017 Business Wire
Oct-09-17 02:19PM  How Should You Think About Ophthotech Corporations (OPHT) Risks? Simply Wall St.
Sep-21-17 10:15AM  How is the Age-Related Macular Degeneration Space Faring Now? Zacks
Sep-19-17 07:00AM  Ophthotech Provides Update on Zimura® Complement Programs for Treatment of Eye Diseases Business Wire
Sep-11-17 09:42AM  Roche's Ophthalmology Drug Fails to Meet Primary Endpoint Zacks
Sep-08-17 01:01PM  Roche shares decline 1.6% on news that late-stage study missed primary endpoint MarketWatch -14.52%
Aug-29-17 06:49AM  Why Is Ophthotech (OPHT) Up 7.4% Since the Last Earnings Report? Zacks
Aug-16-17 10:23AM  Ophthotech's Fovista Combo Regimen Disappoints in Phase III Zacks
Aug-14-17 09:38AM  Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward TheStreet.com +6.27%
06:30AM  Ophthotech Announces Results from Third Phase 3 Trial of Fovista® in Wet Age-Related Macular Degeneration Business Wire
Aug-12-17 11:56AM  Edited Transcript of OPHT earnings conference call or presentation 26-Jul-17 12:00pm GMT Thomson Reuters StreetEvents
Jul-27-17 10:28AM  Ophthotech (OPHT) Q2 Loss Narrows, Focus Shifts to Zimura Zacks -6.64%
Jul-26-17 03:23PM  Ophthotech reports 2Q loss Associated Press
06:45AM  Investor Network: Ophthotech Corp. to Host Earnings Call Accesswire
06:33AM  Ophthotech Reports Second Quarter 2017 Financial and Operating Results Business Wire
06:30AM  Ophthotech Expands Focus with Development for Ophthalmic Orphan Diseases Business Wire
Jul-21-17 07:30AM  Ophthotech Corporation to Report Second Quarter 2017 Financial Results and Host Conference Call on Wednesday, July 26, 2017 Business Wire
Jun-06-17 03:59AM  Why Is Ophthotech (OPHT) Down 13.7% Since the Last Earnings Report? Zacks
May-18-17 03:59PM  Edited Transcript of OPHT earnings conference call or presentation 3-May-17 12:00pm GMT Thomson Reuters StreetEvents
May-15-17 09:00PM  Newman Ferrara LLP Announces Corporate Governance Investigation of Ophthotech Corp. - OPHT Business Wire
May-04-17 10:48AM  Ophthotech (OPHT) Q1 Loss Narrower than Expected, Sales Miss Zacks
May-03-17 07:46PM  Edited Transcript of OPHT earnings conference call or presentation 3-May-17 12:00pm GMT Thomson Reuters StreetEvents
07:52AM  Ophthotech reports 1Q loss Associated Press
07:30AM  Ophthotech Reports First Quarter 2017 Financial and Operating Results Business Wire
07:05AM  Investor Network: Ophthotech Corp. to Host Earnings Call Accesswire
May-01-17 04:15PM  ETFs with exposure to Ophthotech Corp. : May 1, 2017 Capital Cube
Apr-26-17 07:30AM  Ophthotech Corporation to Report First Quarter 2017 Financial Results and Host Conference Call on Wednesday, May 3, 2017 Business Wire
Apr-24-17 04:15PM  Ophthotech Announces Leadership Transition Effective July 1, 2017 Business Wire
Apr-19-17 02:29PM  ETFs with exposure to Ophthotech Corp. : April 19, 2017 Capital Cube
Apr-07-17 05:14PM  ETFs with exposure to Ophthotech Corp. : April 7, 2017 Capital Cube
Mar-31-17 07:45AM  Ophthotech (OPHT) Down 2.9% Since Earnings Report: Can It Rebound? Zacks
07:01AM  OPHTHOTECH CORP. Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders
Mar-27-17 04:02PM  ETFs with exposure to Ophthotech Corp. : March 27, 2017 Capital Cube
04:02PM  ETFs with exposure to Ophthotech Corp. : March 27, 2017
Mar-20-17 08:37AM  Ophthotech Corp. :OPHT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Capital Cube
08:37AM  Ophthotech Corp. :OPHT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
Mar-14-17 02:55PM  Ophthotech Corp. :OPHT-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Capital Cube
02:55PM  Ophthotech Corp. :OPHT-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
Mar-10-17 10:50PM  OPHTHOTECH 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit against Ophthotech Corporation (OPHT) Business Wire
Mar-09-17 11:33AM  EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ophthotech Corporation and Encourages Investors with Losses to Contact the Firm Accesswire
Ophthotech Corporation, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, for dry and wet forms of age-related macular degeneration, a disorder of the central portion of the retina known as the macula. Ophthotech Corporation has a research agreement with the University of Massachusetts Medical School to utilize the minigene therapy approach and novel gene delivery technologies to target retinal diseases. The company was founded in 2007 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Carroll David FrancisSVP, CFO and TreasurerJul 02Sale2.682,7367,3328,980Jul 03 05:10 PM
SBLENDORIO GLENNPresident and CEOApr 02Sale2.696,83818,39448,407Apr 03 07:06 PM
WOOD BARBARA ASVP, Gen. Counsel, SecretaryJan 05Sale3.176021,90816,462Jan 05 05:22 PM
Westby KeithSVP & COOJan 05Sale3.173171,00524,983Jan 05 05:22 PM
GUYER DAVID RExecutive ChairmanJan 05Sale3.173,79812,04038,660Jan 05 05:21 PM
GUYER DAVID RExecutive ChairmanJan 03Sale3.243,51611,39236,208Jan 04 05:13 PM
WOOD BARBARA ASVP, General Counsel,SecretaryJan 03Sale3.246942,24915,864Jan 04 05:09 PM
Westby KeithSVP & COOJan 03Sale3.243561,15324,600Jan 04 05:08 PM
SBLENDORIO GLENNPresident and CEOJan 02Sale3.198,08925,80436,495Jan 03 05:01 PM
WOOD BARBARA ASVP,General Counsel,SecretaryJan 02Sale3.195,28916,87215,183Jan 03 05:02 PM
GUYER DAVID RExecutive ChairmanJan 02Sale3.1916,52052,69933,974Jan 03 05:00 PM